Analysts Set Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Price Target at $14.75

Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) have received a consensus recommendation of “Buy” from the seven research firms that are covering the firm, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $14.75.

A number of analysts recently issued reports on TNYA shares. Chardan Capital decreased their price objective on Tenaya Therapeutics from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Leerink Partners restated an “outperform” rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Piper Sandler restated an “overweight” rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Tenaya Therapeutics in a research note on Monday. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $16.00 target price on shares of Tenaya Therapeutics in a research note on Friday, October 18th.

Tenaya Therapeutics Stock Performance

NASDAQ:TNYA opened at $3.29 on Friday. Tenaya Therapeutics has a 52-week low of $1.61 and a 52-week high of $7.01. The firm has a market cap of $260.63 million, a price-to-earnings ratio of -2.28 and a beta of 2.34. The business’s fifty day moving average is $2.04 and its 200 day moving average is $2.85.

Tenaya Therapeutics (NASDAQ:TNYA) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.07. Equities analysts predict that Tenaya Therapeutics will post -1.35 EPS for the current fiscal year.

Hedge Funds Weigh In On Tenaya Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. The Manufacturers Life Insurance Company boosted its holdings in shares of Tenaya Therapeutics by 43.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company’s stock worth $72,000 after purchasing an additional 7,000 shares in the last quarter. Rhumbline Advisers boosted its holdings in shares of Tenaya Therapeutics by 10.5% in the 2nd quarter. Rhumbline Advisers now owns 78,160 shares of the company’s stock worth $242,000 after purchasing an additional 7,441 shares in the last quarter. State Street Corp boosted its holdings in shares of Tenaya Therapeutics by 0.9% in the 3rd quarter. State Street Corp now owns 1,058,898 shares of the company’s stock worth $2,044,000 after purchasing an additional 9,506 shares in the last quarter. Synovus Financial Corp purchased a new position in shares of Tenaya Therapeutics in the 3rd quarter worth about $28,000. Finally, XTX Topco Ltd boosted its holdings in shares of Tenaya Therapeutics by 51.2% in the 3rd quarter. XTX Topco Ltd now owns 49,290 shares of the company’s stock worth $95,000 after purchasing an additional 16,687 shares in the last quarter. 90.54% of the stock is currently owned by hedge funds and other institutional investors.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.